{"classes":[{"categories":[{"measurements":[{"comment":"The 95% upper confidence limit was not reached.","groupId":"OG000","lowerLimit":"3.8","upperLimit":"NA","value":"11.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Progression-free survival time is defined as the time from registration to the earliest date of documentation of disease progression or death, whichever occurs first. Progression is defines as having any new lesion or increase by 50% of previously involved sites from nadir. The distribution of progression-free survival time will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Rituximab 375 mg/m2 IV on day 1\n\n\\> Cyclophosphamide 300 mg/m2 PO on days 1, 8, 15, 22\n\n\\> Bortezomib 1.3 mg/m2 IV on days 1, 8, 15, 22\n\n\\> Dexamethasone 40 mg PO on days 1, 8, 15, 22","id":"OG000","title":"Treatment"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 3 years from registration","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}